Those at intermediate-to-high risk of recurrence after definitive therapy exhibit advanced disease based on tumour size or lymph node involvement , non-oropharynx primary sites , human papillomavirus ( HPV ) - negative oropharyngeal cancer , or HPV-positive oropharynx cancer with smoking history ( > 10-pack-years ) .